Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT03941964
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers /ID# 211508, Lone Tree, Colorado, United States
🇺🇸Tennessee Oncology - Chattanooga / McCallie /ID# 212717, Chattanooga, Tennessee, United States
🇺🇸Prisma Health Cancer Inst - Eastside /ID# 211466, Greenville, South Carolina, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 29
- Registration Number
- NCT03875287
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT03855371
- Locations
- 🇨🇳
Hematological department, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai, Shanghai, China
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 26
- Registration Number
- NCT03844815
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03828084
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT03799224
- Locations
- 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
- Conditions
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT03793517
- Locations
- 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Prostate Carcinoma in the Soft TissuePSA ProgressionCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Prostate Carcinoma Metastatic in the BonePSA Level Greater Than or Equal to Two
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03709550
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia
- Conditions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Capital Research Institute of Pediatrics
- Target Recruit Count
- 6
- Registration Number
- NCT03687463
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.